DR. LAL PATH LABS
Dr.Lal Path Labs Limited is an international service provider of diagnostic and related healthcare tests, headquartered in Delhi. It was founded in the year 1949 by Dr. S.K.Lal. The main operation of the laboratory is to perform diagnosis and testing, including routine tests and preventive tests. The company has 200 laboratories and diagnostic centres with approximately 1500 collection centres across India. At present, they are the largest diagnostics chain in the country with PAN India presence and consistent track record of quality and growth.
In the year 2013, Lal Path Labs was recognized at the Best Diagnostic Service Company by VCCircle. This laboratory is present in various parts of the world and prides itself on providing high quality services combines with 100% accurate reports, patient centric service outlook, state-of-the-art technology etc. They have centres in Saudi Arabia, UAE, Nigeria, Bangladesh, and Sri Lanka to name a few. Their range of services include: Pathology testing, Radiology Testing, Lab staff training, Technical Services, Lab management services and quality assurance programme. They have 1000+ field executives, 6000+ pick up points across India and 15+ countries covered.
The company has performed more than usual number of tests because of COVID-19 which resulted in the increase in their revenue by 17%. The shareholding pattern consist of: Promoters having (52.23% shares), FIIs having (26.01% shares), DIIs having (7.52% shares), Public having (5.76% shares) and Others (4.61% shares).
For the year quarter ending 31-03-2021, the company recorded an increase of 42.9% in its revenue which stands at Rs.431 Cr. against Rs.301.7 Cr last year same time. The PAT also jumped by 161.0% and now stands at Rs.85.1Cr against Rs.32.6 Cr. The Non-COVID business achieved a phenomenal increase with 26.8% growth YoY, and the testing resulted in a hike as caseloads rose in March again because of the second wave of COVID-19 in India. The Non-COVID business revenues stood at Rs.392.5 Cr in Q4 FY21 and the patients’ volume grew by 33.3% YoY to 5.9 million. The CFO of the company surged by 40% and now stands at Rs.398 Cr. The boards of directors declared a final dividend of Rs.8 per equity share of Rs.10 each. The company performed notably well for the Q4 FY21, and has also helped the healthcare system of India with its services tremendously well in the hour of need.
